Fibrosis Clinical Trial
Official title:
A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | June 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: - Aged =40 to 80 years at the time of signing the informed consent. - Diagnosis of IPF within 5 years of Screening based on the modified ATS/ERS/JRS/ALAT IPF guidelines for diagnosis and management of IPF (Raghu et al, 2018) and confirmed on independent central imaging review. - Combination of HRCT pattern, as assessed by central reviewers, consistent with diagnosis of IPF (see the modified ATS/ERS/JRS/ALAT IPF guidelines [Raghu et al, 2018]). - FVC % predicted =50% predicted of normal at Screening, with no clinically significant deterioration between the Screening Visit and randomisation, as determined by the Investigator. - DLco (Hb-adjusted) at screening =30%. - In the main study, participants receiving treatment for IPF with nintedanib or pirfenidone are allowed if on treatment for at least 3 months and on a stable dose for at least 4 weeks prior to Screening and during Screening. - In patients who are not on any treatment for IPF but have previously received nintedanib or pirfenidone, there needs to be a washout period =4 weeks prior to Screening. - No clinically significant abnormalities, in the opinion of the investigator, in vital signs (e.g., blood pressure, pulse rate, respiration rate, oral temperature) within 28 days before first dose of IMP. Exclusion Criteria: - Currently receiving or planning to initiate treatment for IPF with agents not approved for that indication. - FEV1/FVC ratio <0.7 at Screening, pre-bronchodilator use. - Lower respiratory tract infection requiring antibiotics within 4 weeks of Screening or during Screening. 4. The extent of emphysema in the lungs exceeds fibrosis, based on central review of HRCT scans. - Need for continuous oxygen supplementation, defined as >15 hours/day. - Acute IPF exacerbation within 6 months of Screening or during Screening. - Clinical diagnosis of any connective-tissue disease (including, but not limited to, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis) or a diagnosis of interstitial pneumonia with autoimmune features as determined by the Investigator applying the recent ERS/ATS research statement [Fischer et al 2015]. Note: Serological testing is not needed if not clinically indicated. - Disease other than IPF with a life expectancy of less than 12 weeks. Additional exclusion criteria for the Translational Science Sub Study - Participants with any contra-indication to bronchoscopy and alveolar lavage including tracheal stenosis, pulmonary hypertension, severe hypoxia, or hypercapnia. - Patients in the sub study are not permitted to receive nintedanib or pirfenidone within 3 weeks of randomisation and throughout the Treatment period. (Note: background IPF treatment should not be stopped for the purpose of eligibility) |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Wien | |
Belgium | E PNE UZ Leuven | Leuven | |
Belgium | CHU De Liège | Liège | |
Czechia | Pneumologicka klinika 1.LF UK a | Praha | |
Italy | Azienda Ospedaliero-Universitaria "Ospedali-Riuniti" di Ancona | Ancona | |
Italy | Azienda Ospedaliero Universitaria Policlinico ''G.Rodolico-San Marco'' | Catania | |
Italy | Colonello D'avanzo Hospital | Foggia | |
Italy | PO Vito Fazzi | Lecce | |
Italy | Ospedale S. Giuseppe Milano | Milan | |
Italy | Azienda Ospedaliera Universitaria of Modena | Modena | |
Italy | Fondazione Policlinico Universitario A. Gemelli | Roma | |
Italy | Azienda Ospedaliera Universitaria Integrata Verona | Verona | |
Poland | University Clinical Centre in Gdansk | Gdansk | |
Poland | Barlicki University Hospital | Lodz | |
Poland | Institute of Tuberculosis and Lung Diseases in Warsaw | Warsaw | |
Spain | Hospital Universitario Clínic de Barcelona | Barcelona | |
Spain | L'Hospital Universitari de Bellvitge | Barcelona | |
Spain | Policlinica Barcelona | Barcelona | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Central de Asturias | Oviedo | |
Spain | Hospital Universitario Marqués de Valdecilla | Santander | |
Spain | Hospital Clínico Universitario de Santiago de Compostela | Santiago De Compostela | |
Switzerland | University Hospital of Geneve | Geneva | |
United Kingdom | Belfast City Hospital | Belfast | |
United Kingdom | Queen Elizabeth Hospital | Birmingham | |
United Kingdom | Royal Papworth Hospital NHSFT | Cambridge | |
United Kingdom | Royal Infirmary of Edinburgh | Edinburgh | |
United Kingdom | Guy's Hospital | London | |
United Kingdom | Royal Brompton Hospital | London | |
United Kingdom | Altnagelvin Area Hospital | Londonderry | |
United Kingdom | Churchill Hospital, Oxford University Hospitals NHS Trust | Oxford | |
United States | Baylor Clinic | Houston | Texas |
United States | University of Southern California - Center for Advanced Lung Disease | Los Angeles | California |
United States | Temple University, Dept of Thoracic Medicine & Surgery (TMS) | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Redx Pharma Plc | Simbec Research |
United States, Austria, Belgium, Czechia, Italy, Poland, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of AEs and SAEs Changes in safety laboratory parameters, vital signs, and ECGs | The primary endpoints of the study include the incidence and severity of AEs and SAEs | From Day 1 to post-study follow up visit (12 weeks) | |
Primary | Number of participants who report a change from normal range values for laboratory safety parameters (serum biochemistry, serum haematology or urinalysis) from first dose on Day 1 to post-study follow up visit. | This primary endpoint will report the number of participants within all cohorts of study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the serum biochemistry, serum haematology or urinalysis parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the post-study visit | From Day 1 to post-study follow up visit (12 weeks) | |
Primary | Number of participants who report a change from normal range values for vital signs parameters (blood pressure, pulse rate, respiration rate, oral body temperature) from first dose on Day 1 to 12 weeks of treatment | This primary endpoint will report the number of participants within all cohorts of the study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the vital signs parameters (systolic/diastolic blood pressure, pulse rate, respiration rate, oral body temperature) as defined in the study protocol following first dose administration on Day 1 up to completion of the post-study visit | From Day 1 to post-study follow up visit (12 weeks) | |
Primary | Number of participants who report a change from normal range values for any of the associated 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) from first dose on Day 1 up to completion of the post-study visit. | This primary endpoint will report the number of participants within all cohorts of the study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) as defined in the study protocol following first dose administration on Day 1 up to 12 weeks of treatment | From Day 1 to post-study follow up visit (12 weeks) | |
Secondary | Pharmacokinetic Parameters - Maximum plasma concentration (Cmax) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the maximum observed concentration (Cmax) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Minimum observed plasma concentration (Cmin) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the minimum observed concentration (Cmin) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Time to maximum observed concentration (Tmax) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the time to maximum observed concentration (Tmax) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Terminal elimination half-life (t1/2) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the terminal elimination half-life (t1/2) of RXC007 in plasma for all cohorts | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Elimination rate constant (?z) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the elimination rate constant (?z) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Area under the concentration-time curve (AUC) extrapolated to infinity (AUC0-inf) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve (AUC) extrapolated to infinity (AUC0-inf) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Total apparent clearance following extravascular administration (CL/F) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the total apparent clearance following extravascular administration (CL/F) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Apparent volume of distribution following extravascular administration (Vz/F) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the apparent volume of distribution following extravascular administration (Vz/F) of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | Pharmacokinetic Parameters - Area under the plasma concentration-time curve during a dosing interval at steady state (AUCss) | Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve (AUC) at steady state of RXC007 in plasma for all cohorts. | For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose. | |
Secondary | % predicted and absolute volume change from baseline in Forced Vital Capacity (FVC) at 12 weeks [central review] | Information on Forced Vital Capacity (FVC) for the 6 months prior to study entry will be collected. Spirometry testing (without bronchodilator use) will be performed at all scheduled study visits in clinic. For each patient, spirometry testing should be conducted at approximately the same time of day. | At Screening (Day28 to Day-1), Cycle1 Day1 pre-dose and post-dose, Cycle1 Day8, Cycle1 Day15, Cycle1 Day22, Cycle2 Day1(The day after Cycle1 Day28), Cycle2 Day15, Cycle3 Day1, Cycle3 Day28, End Of Treatment: last day of the dosing Day 21 | |
Secondary | % predicted and absolute change from baseline in carbon monoxide diffusion capacity (DLCO) | Carbon monoxide diffusion capacity will be measured in clinic | At Screening (day28 to Day-1), Cycle1 Day1 pre-dose, Cycle1 Day15, Cycle2 Day1 (The day after Cycle1 Day28) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03979417 -
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
|
||
Completed |
NCT02408744 -
Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00148837 -
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
|
Phase 2 | |
Recruiting |
NCT05661123 -
Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis
|
N/A | |
Recruiting |
NCT04795570 -
Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
|
||
Active, not recruiting |
NCT05075785 -
Covid-19 Respiratory Sequelae French Cohort
|
||
Recruiting |
NCT03308916 -
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
|
N/A | |
Recruiting |
NCT05459259 -
Physiotherapy for Arthrofibrosis Following Knee Replacement.
|
||
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00001729 -
Combination Drug Therapy for Patients With Hepatitis C
|
Phase 3 | |
Completed |
NCT02049307 -
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
|
Phase 2 | |
Active, not recruiting |
NCT05685823 -
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
|
||
Completed |
NCT00744939 -
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
|
Phase 4 | |
Completed |
NCT00252642 -
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
|
N/A | |
Recruiting |
NCT04934202 -
Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
|
||
Completed |
NCT02604862 -
Imaging FIB ONE in the Human Lung Using Endomicroscopy
|
Early Phase 1 | |
Completed |
NCT02774161 -
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
|
N/A | |
Active, not recruiting |
NCT01246388 -
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
|
N/A | |
Completed |
NCT02161952 -
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
|
Phase 2 | |
Completed |
NCT00347009 -
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
|
Phase 4 |